Compare Amphastar Pharmaceuticals Inc (AMPH) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Main Street Capital Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Main Street Capital Corporation trades at $52.89 (market cap $4.91B). The key difference: Main Street Capital Corporation is far larger — about 5.9× Amphastar Pharmaceuticals Inc's market cap, and Main Street Capital Corporation pays a 8.29% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MAIN | |
|---|---|---|
Market Cap | $826.08M | $4.91B |
Sector | Health | Financials |
52-Week High | $30.81 | $67.54 |
52-Week Low | $16.87 | $49.63 |
Enterprise Value | $1.22B | — |
Dividend Yield | — | 8.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Main Street Capital (MAIN) trades at $52.84, up 2.26% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong profitability with an 81.08% net margin and 14.37% ROE, though recent quarters show inconsistent earnings performance with two misses and one beat. Revenue declined slightly from $601M in 2024 to $592M in 2025, with further contraction projected for 2026. The stock pays consistent dividends, with recent payments ranging from $0.26 to $0.30 per share.
MAIN presents a cautious outlook with analysts showing 78.57% hold ratings despite a $57.75 consensus price target suggesting 9.3% upside. The bearish technical trend and projected revenue decline to $526M in 2026 create headwinds, while strong profitability metrics and dividend consistency provide support. Investors face balancing attractive valuation (P/E 11.12) against earnings volatility and negative operating cash flow of -$45.71M in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
